A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

NCT00508625 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: AMG 951 (rhApo2L/TRAIL)
DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Amgen

Collaborators

[object Object]